p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential.

MLA

Navone, N. M., et al. “P53 Mutations in Prostate Cancer Bone Metastases Suggest That Selected P53 Mutants in the Primary Site Define Foci with Metastatic Potential.” The Journal of Urology, vol. 161, no. 1, Jan. 1999, pp. 304–08. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=10037428&authtype=sso&custid=ns315887.

APA

Navone, N. M., Labate, M. E., Troncoso, P., Pisters, L. L., Conti, C. J., von Eschenbach, A. C., & Logothetis, C. J. (1999). p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential. The Journal of Urology, 161(1), 304–308.

Chicago

Navone, N M, M E Labate, P Troncoso, L L Pisters, C J Conti, A C von Eschenbach, and C J Logothetis. 1999. “P53 Mutations in Prostate Cancer Bone Metastases Suggest That Selected P53 Mutants in the Primary Site Define Foci with Metastatic Potential.” The Journal of Urology 161 (1): 304–8. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=10037428&authtype=sso&custid=ns315887.